Cindy Martinez
Research Subjects
Cindy Martinez has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
Carmen Guerrero
Department of Noncommunicable Diseases and Mental Health Pan American Health Organization Country Office Ecuador
3 shared publicationsDaniela Zavando
Department of Noncommunicable Diseases and Mental Health Pan American Health Organization Country Office Chile
3 shared publicationsEdgar Rivera
Department of Noncommunicable Diseases and Mental Health Pan American Health Organization Country Office Venezuela
3 shared publicationsEssy Maradiegue
Division of Cancer Ministry of Health Lima Peru
3 shared publicationsGisela Vargas
National Cancer Program Ministry of Health Caracas Venezuela
3 shared publicationsJuan Arturo Sabinés
Department of Noncommunicable Diseases and Mental Health Pan American Health Organization Country Office Colombia
3 shared publications
Latest Publications
- 5 October 2026
- Published by Wiley in Pediatric Blood & Cancer
- p. e70713
Implementing a South–South Cooperation Model to Strengthen Early Diagnosis of Childhood Cancer in the Andean Subregion
Background: This project aims to promote early diagnosis of childhood cancer in the Andean subregion through South–South cooperation to strengthen health‐system capacity. It was implemented within the WHO Global Initiative for Childhood Cancer (GICC) and the PAHO Cooperation Among Countries for Health Development (CCHD) mechanism, led by the Pan American Health Organization (PAHO), the Andean Health Organization (ORAS‐CONHU), and St. Jude Children's Research Hospital. Methods: Between April 2023 and July 2024, seed funding supported South–South cooperation activities to strengthen early diagnosis through education, communication, and collaboration. A monitoring and sustainability phase was conducted from August 2024 to December 2025. The assessment focused on implementation activities and programmatic outputs, while available country‐level indicators of diagnostic timeliness were reviewed descriptively. Results: The initiative supported implementation of a regional South–South cooperation model across six Andean countries. Outputs included training 61,502 participants through virtual activities and 4,114 through in‐person activities, development and adaptation of communication materials, community awareness campaigns, strengthened national and regional coordination mechanisms, and incorporation of early diagnosis activities into national policy and cancer control frameworks. Country‐level data on diagnostic timeliness were available only in selected settings and were not sufficiently standardized for regional assessment of impact. Conclusions: This initiative demonstrates the feasibility of South–South cooperation to support regional capacity building, health‐system strengthening, and policy development for childhood cancer early diagnosis. The experience highlights the value of shared knowledge, resource optimization, regional coordination, and adaptation to local contexts. Longer‐term standardized monitoring is needed to determine whether these implementation outputs translate into measurable improvements in early diagnosis and other patient‐level outcomes.
- 5 October 2026
- Published by Wiley in Pediatric Blood & Cancer
- p. e70713
Implementing a South–South Cooperation Model to Strengthen Early Diagnosis of Childhood Cancer in the Andean Subregion
Background: This project aims to promote early diagnosis of childhood cancer in the Andean subregion through South–South cooperation to strengthen health‐system capacity. It was implemented within the WHO Global Initiative for Childhood Cancer (GICC) and the PAHO Cooperation Among Countries for Health Development (CCHD) mechanism, led by the Pan American Health Organization (PAHO), the Andean Health Organization (ORAS‐CONHU), and St. Jude Children's Research Hospital. Methods: Between April 2023 and July 2024, seed funding supported South–South cooperation activities to strengthen early diagnosis through education, communication, and collaboration. A monitoring and sustainability phase was conducted from August 2024 to December 2025. The assessment focused on implementation activities and programmatic outputs, while available country‐level indicators of diagnostic timeliness were reviewed descriptively. Results: The initiative supported implementation of a regional South–South cooperation model across six Andean countries. Outputs included training 61,502 participants through virtual activities and 4,114 through in‐person activities, development and adaptation of communication materials, community awareness campaigns, strengthened national and regional coordination mechanisms, and incorporation of early diagnosis activities into national policy and cancer control frameworks. Country‐level data on diagnostic timeliness were available only in selected settings and were not sufficiently standardized for regional assessment of impact. Conclusions: This initiative demonstrates the feasibility of South–South cooperation to support regional capacity building, health‐system strengthening, and policy development for childhood cancer early diagnosis. The experience highlights the value of shared knowledge, resource optimization, regional coordination, and adaptation to local contexts. Longer‐term standardized monitoring is needed to determine whether these implementation outputs translate into measurable improvements in early diagnosis and other patient‐level outcomes.
- 22 January 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (4) , e70130
Bridging the Gap: Regional Disparities in Access to Pediatric Hematopoietic Stem Cell Transplantation (HSCT) in the Andean Subregion
Background: Pediatric hematopoietic stem cell transplantation (HSCT) is a life‐saving therapy for malignant and non‐malignant hematologic diseases. However, access to this high‐complexity treatment remains limited and uneven across the Andean subregion. This study aimed to evaluate the current status, capacity, and equity of pediatric HSCT programs in six Andean countries (Bolivia, Chile, Colombia, Ecuador, Peru, and Venezuela) within the framework of WHO Global Initiative of Childhood Cancer. Methods: A mixed‐methods, cross‐sectional situational assessment was conducted between November 2024 and January 2025 under the coordination of the Andean Health Organization (ORAS‐CONHU) and the Pan American Health Organization (PAHO). Standardized national and center‐level surveys (34 and 150 items, respectively) were applied to Ministries of Health and HSCT centers to collect data on infrastructure, workforce, financing, quality management, and barriers to access. Quantitative data were analyzed descriptively and validated by national committees, complemented by qualitative interviews with key stakeholders. Results: Twenty‐seven HSCT centers were identified across the subregion, revealing major disparities in access and capacity. Chile reached 100% coverage of estimated transplant needs, whereas Colombia, Peru, and Venezuela achieved 80%, 29%, and 42.5%, respectively. Bolivia and Ecuador had the lowest coverage (1.6% and 24%). Only 28% of units were pediatric‐exclusive, and less than two‐thirds met full quality and training standards. High‐cost medicines, limited infrastructure, and shortages of specialized personnel were identified as critical barriers, whereas regional collaboration and national policies emerged as key facilitators. Conclusion: The study highlights significant inequities in pediatric HSCT access and capacity across the Andean subregion. Strengthening infrastructure, workforce training, financing mechanisms, and data systems, supported by sustained regional cooperation, is essential to achieve equitable, high‐quality transplant care for all children.
- 22 January 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (4) , e70130
Bridging the Gap: Regional Disparities in Access to Pediatric Hematopoietic Stem Cell Transplantation (HSCT) in the Andean Subregion
Background: Pediatric hematopoietic stem cell transplantation (HSCT) is a life‐saving therapy for malignant and non‐malignant hematologic diseases. However, access to this high‐complexity treatment remains limited and uneven across the Andean subregion. This study aimed to evaluate the current status, capacity, and equity of pediatric HSCT programs in six Andean countries (Bolivia, Chile, Colombia, Ecuador, Peru, and Venezuela) within the framework of WHO Global Initiative of Childhood Cancer. Methods: A mixed‐methods, cross‐sectional situational assessment was conducted between November 2024 and January 2025 under the coordination of the Andean Health Organization (ORAS‐CONHU) and the Pan American Health Organization (PAHO). Standardized national and center‐level surveys (34 and 150 items, respectively) were applied to Ministries of Health and HSCT centers to collect data on infrastructure, workforce, financing, quality management, and barriers to access. Quantitative data were analyzed descriptively and validated by national committees, complemented by qualitative interviews with key stakeholders. Results: Twenty‐seven HSCT centers were identified across the subregion, revealing major disparities in access and capacity. Chile reached 100% coverage of estimated transplant needs, whereas Colombia, Peru, and Venezuela achieved 80%, 29%, and 42.5%, respectively. Bolivia and Ecuador had the lowest coverage (1.6% and 24%). Only 28% of units were pediatric‐exclusive, and less than two‐thirds met full quality and training standards. High‐cost medicines, limited infrastructure, and shortages of specialized personnel were identified as critical barriers, whereas regional collaboration and national policies emerged as key facilitators. Conclusion: The study highlights significant inequities in pediatric HSCT access and capacity across the Andean subregion. Strengthening infrastructure, workforce training, financing mechanisms, and data systems, supported by sustained regional cooperation, is essential to achieve equitable, high‐quality transplant care for all children.
- Open Access
- 25 November 2025
- Published by Wiley
Bridging the Gap: Regional Disparities in Access to Pediatric Hematopoietic Stem Cell Transplantation (HSCT) in the Andean Subregion
Background Pediatric hematopoietic stem cell transplantation (HSCT) is a life-saving therapy for malignant and non-malignant hematologic diseases. However, access to this high-complexity treatment remains limited and uneven across the Andean subregion. This study aimed to evaluate the current status, capacity, and equity of pediatric HSCT programs in six Andean countries (Bolivia, Chile, Colombia, Ecuador, Peru, and Venezuela) within the framework of WHO Global Initiative of Childhood Cancer. Methods A mixed-methods, cross-sectional situational assessment was conducted between November 2024 and January 2025 under the coordination of the Andean Health Organization (ORAS-CONHU) and the Pan American Health Organization (PAHO). Standardized national and center-level surveys (34 and 150 items, respectively) were applied to Ministries of Health and HSCT centers to collect data on infrastructure, workforce, financing, quality management, and barriers to access. Quantitative data were analyzed descriptively and validated by national committees, complemented by qualitative interviews with key stakeholders. Results Twenty-seven HSCT centers were identified across the subregion, revealing major disparities in access and capacity. Chile reached 100% coverage of estimated transplant needs, while Colombia, Peru, and Venezuela achieved 80%, 29%, and 42.5%, respectively. Bolivia and Ecuador had the lowest coverage (1.6% and 24%). Only 28% of units were pediatric-exclusive, and less than two-thirds met full quality and training standards. High-cost medicines, limited infrastructure, and shortages of specialized personnel were identified as critical barriers, while regional collaboration and national policies emerged as key facilitators. Conclusion The study highlights significant inequities in pediatric HSCT access and capacity across the Andean subregion. Strengthening infrastructure, workforce training, financing mechanisms, and data systems, supported by sustained regional cooperation, is essential to achieve equitable, high-quality transplant care for all children.
- 25 November 2025
- Published by Wiley
Open AccessBridging the Gap: Regional Disparities in Access to Pediatric Hematopoietic Stem Cell Transplantation (HSCT) in the Andean Subregion
Background Pediatric hematopoietic stem cell transplantation (HSCT) is a life-saving therapy for malignant and non-malignant hematologic diseases. However, access to this high-complexity treatment remains limited and uneven across the Andean subregion. This study aimed to evaluate the current status, capacity, and equity of pediatric HSCT programs in six Andean countries (Bolivia, Chile, Colombia, Ecuador, Peru, and Venezuela) within the framework of WHO Global Initiative of Childhood Cancer. Methods A mixed-methods, cross-sectional situational assessment was conducted between November 2024 and January 2025 under the coordination of the Andean Health Organization (ORAS-CONHU) and the Pan American Health Organization (PAHO). Standardized national and center-level surveys (34 and 150 items, respectively) were applied to Ministries of Health and HSCT centers to collect data on infrastructure, workforce, financing, quality management, and barriers to access. Quantitative data were analyzed descriptively and validated by national committees, complemented by qualitative interviews with key stakeholders. Results Twenty-seven HSCT centers were identified across the subregion, revealing major disparities in access and capacity. Chile reached 100% coverage of estimated transplant needs, while Colombia, Peru, and Venezuela achieved 80%, 29%, and 42.5%, respectively. Bolivia and Ecuador had the lowest coverage (1.6% and 24%). Only 28% of units were pediatric-exclusive, and less than two-thirds met full quality and training standards. High-cost medicines, limited infrastructure, and shortages of specialized personnel were identified as critical barriers, while regional collaboration and national policies emerged as key facilitators. Conclusion The study highlights significant inequities in pediatric HSCT access and capacity across the Andean subregion. Strengthening infrastructure, workforce training, financing mechanisms, and data systems, supported by sustained regional cooperation, is essential to achieve equitable, high-quality transplant care for all children.
- Open Access
- 1 November 2022
- Published by Asociacion Colombiana de Hematologia y Oncologia in Revista Colombiana de Hematología y Oncología
- Vol. 9 (1) , 10-18
Caracterización de pacientes pediátricos con meduloblastoma tratados en un centro de referencia en Bogotá en el periodo 2011 a 2018
Central nervous system (CNS) tumors are the most prevalent solid neoplasms in pediatrics. Medullo- blastoma is the most frequent embryonal tumor of the CNS and corresponds to approximately 20% of cases. Objective: to describe the experience in the diagnosis, treatment, and results of patients with medulloblastoma in a reference center in Colombia. Methods: 38 patients were included from January 2011 to December 2018. Results: those under 3 years of age received treatment based on the CCG9921 protocol and those over 3 years of age treatment based on the ACNS0332 protocol. Overall survival at 5 years was 50.6%. The overall survival of the entire group is low compared to countries with higher incomes due to multiple factors such as access barriers. Conclusion: It is im- portant to establish national guidelines that allow earlier diagnosis and risk-adjusted treatment. Also, it is important to collect information from multiple centers in order to evaluate the results and propose improvements in health policies.
- 1 November 2022
- Published by Asociacion Colombiana de Hematologia y Oncologia in Revista Colombiana de Hematología y Oncología
- Vol. 9 (1) , 10-18
Open AccessCaracterización de pacientes pediátricos con meduloblastoma tratados en un centro de referencia en Bogotá en el periodo 2011 a 2018
Central nervous system (CNS) tumors are the most prevalent solid neoplasms in pediatrics. Medullo- blastoma is the most frequent embryonal tumor of the CNS and corresponds to approximately 20% of cases. Objective: to describe the experience in the diagnosis, treatment, and results of patients with medulloblastoma in a reference center in Colombia. Methods: 38 patients were included from January 2011 to December 2018. Results: those under 3 years of age received treatment based on the CCG9921 protocol and those over 3 years of age treatment based on the ACNS0332 protocol. Overall survival at 5 years was 50.6%. The overall survival of the entire group is low compared to countries with higher incomes due to multiple factors such as access barriers. Conclusion: It is im- portant to establish national guidelines that allow earlier diagnosis and risk-adjusted treatment. Also, it is important to collect information from multiple centers in order to evaluate the results and propose improvements in health policies.
- Open Access
- 4 March 2022
- Published by Elsevier in Pediatric Hematology Oncology Journal
- Vol. 7 (1) , 1-3
Association between early risk factors and CDKN2A/B deletion in pediatric patients with acute lymphoblastic leukemia in a pediatric cancer center in Colombia
- 4 March 2022
- Published by Elsevier in Pediatric Hematology Oncology Journal
- Vol. 7 (1) , 1-3
Open AccessAssociation between early risk factors and CDKN2A/B deletion in pediatric patients with acute lymphoblastic leukemia in a pediatric cancer center in Colombia
- Open Access
- 17 November 2021
- Published by Wiley in Cancer Reports
- Vol. 5 (5) , e1587
Philadelphia‐like acute lymphoblastic leukemia: Characterization in a pediatric cohort in a referral center in Colombia
Background: Philadelphia‐like (Ph‐like) acute lymphoblastic leukemia (ALL) is a subtype of pediatric leukemia with high risk factors and poor outcome. There are few reports of its prevalence in Latin America.Aim: This study evaluated the frequency and clinical and biological characteristics of Ph‐like ALL in a pediatric cancer center in Colombia.Methods: The Ph‐like genetic profile was analyzed by a low‐density array (LDA). Samples from patients with Ph‐like ALL were analyzed by fluorescent in situ hybridization for cytokine receptor like factor 2 (CRLF2) and ABL proto‐oncogene 1, non‐receptor tyrosine kinase (ABL1) rearrangements. Copy number variations were assessed by multiplex ligation probe amplification.Results: Data from 121 patients were analyzed. Fifteen patients (12.4%) had Ph‐like ALL, and these patients had significantly higher leukocyte counts at diagnosis and higher levels of minimal residual disease on days 15 and 33 of induction than patients without the Ph‐like subtype. There were no significant differences in sex, age, or response to prednisone at day 8 between the two groups. CRLF2 rearrangements were identified in eight patients, and ABL1 rearrangements were identified in two patients. Other genetic alterations alone or in combination were identified in 77% of patients, including deletions in cyclin dependent kinase inhibitor 2 A/B (46.2%), IKAROS family zinc finger 1 (38.3%), and paired box 5 (30.8%).Conclusions: Ph‐like ALL had a 12.4% prevalence in our cohort of patients with pediatric ALL. The identification of this group of patients has importance for risk stratification and future targeted therapy.
- 17 November 2021
- Published by Wiley in Cancer Reports
- Vol. 5 (5) , e1587
Open AccessPhiladelphia‐like acute lymphoblastic leukemia: Characterization in a pediatric cohort in a referral center in Colombia
Background: Philadelphia‐like (Ph‐like) acute lymphoblastic leukemia (ALL) is a subtype of pediatric leukemia with high risk factors and poor outcome. There are few reports of its prevalence in Latin America.Aim: This study evaluated the frequency and clinical and biological characteristics of Ph‐like ALL in a pediatric cancer center in Colombia.Methods: The Ph‐like genetic profile was analyzed by a low‐density array (LDA). Samples from patients with Ph‐like ALL were analyzed by fluorescent in situ hybridization for cytokine receptor like factor 2 (CRLF2) and ABL proto‐oncogene 1, non‐receptor tyrosine kinase (ABL1) rearrangements. Copy number variations were assessed by multiplex ligation probe amplification.Results: Data from 121 patients were analyzed. Fifteen patients (12.4%) had Ph‐like ALL, and these patients had significantly higher leukocyte counts at diagnosis and higher levels of minimal residual disease on days 15 and 33 of induction than patients without the Ph‐like subtype. There were no significant differences in sex, age, or response to prednisone at day 8 between the two groups. CRLF2 rearrangements were identified in eight patients, and ABL1 rearrangements were identified in two patients. Other genetic alterations alone or in combination were identified in 77% of patients, including deletions in cyclin dependent kinase inhibitor 2 A/B (46.2%), IKAROS family zinc finger 1 (38.3%), and paired box 5 (30.8%).Conclusions: Ph‐like ALL had a 12.4% prevalence in our cohort of patients with pediatric ALL. The identification of this group of patients has importance for risk stratification and future targeted therapy.